Related Experiment Video
Updated: Jun 18, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.4K
Development and Challenges of Pre-Heart Failure with Preserved Ejection Fraction
Guoju Dong1,2
1Department of Cardiovascular Internal Medicine, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine, 100091 Beijing, China.
Reviews in Cardiovascular Medicine
|July 30, 2024
Summary
Early recognition of pre-heart failure with preserved ejection fraction (Pre-HFpEF) can prevent the progression to heart failure with preserved ejection fraction (HFpEF). This review covers Pre-HFpEF
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Clinical Science
Background:
- Pre-heart failure with preserved ejection fraction (Pre-HFpEF) represents an early stage preceding heart failure with preserved ejection fraction (HFpEF).
- Identifying and intervening in Pre-HFpEF is crucial for preventing HFpEF development.
Purpose of the Study:
- To explore the concept, development, and evolution of Pre-HFpEF.
- To elucidate the underlying mechanisms and associated risks of Pre-HFpEF.
- To review screening methods and therapeutic strategies for Pre-HFpEF.
Main Methods:
- Literature review and conceptual analysis.
- Discussion of pathophysiological mechanisms and risk factors.
- Examination of current and emerging screening and treatment modalities.
Main Results:
- Pre-HFpEF is a distinct clinical entity with identifiable mechanisms and risks.
- Effective screening tools are essential for early detection.
- Timely interventions hold the potential to halt HFpEF progression.
Conclusions:
- Focusing on Pre-HFpEF is vital for advancing cardiovascular medicine.
- Further research and clinical attention are needed to address challenges and optimize management.
- Early management of Pre-HFpEF can significantly impact patient outcomes and reduce HFpEF incidence.
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: Diuretics
355
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
01:26Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
01:22Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332